NEW YORK, July 28 (GenomeWeb News) - Using its systems pharmacology platform, BG Medicine will examine the effects of drugs in tissue and discover plasma biomarkers in an agreement with Boehringer Ingelheim Pharmaceuticals, the companies said today in a statement.
The companies declined to disclose financial details.